Clot lifespan model analysis of the effects of warfarin on thrombus growth and fibrinolysis: Role of contact protein and tissue factor initiation

ASAIO Journal

Volumn 55, Issue 1, 2009, Pages 33-40

  Nielsen, Vance G ^a,b   Kirklin, James K ^b   Holman, William L ^b   Steenwyk, Brad L ^a  

^a UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^b Kentucky   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICOAGULATION THERAPY; CLOT FORMATION; CONTACT ACTIVATION; INTERNATIONAL NORMALIZED RATIOS; LIFE SPAN; LINEAR RELATIONSHIPS; MODEL ANALYSIS; PARAMETER VALUES; PLASMA SAMPLES; TIME TO MAXIMUM RATE; TISSUE FACTORS; TISSUE-TYPE PLASMINOGEN ACTIVATOR (TPA);

BIOLOGICAL MATERIALS; PLASMAS;

CHEMICAL ACTIVATION;

INFUSORIAL EARTH; THROMBOPLASTIN; TISSUE PLASMINOGEN ACTIVATOR; WARFARIN; ANTICOAGULANT AGENT;

ARTICLE; BLOOD CLOT; BLOOD CLOT LYSIS; BLOOD CLOTTING; BLOOD SAMPLING; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG EFFECT; DRUG EXPOSURE; FIBRINOLYSIS; HUMAN; INTERNATIONAL NORMALIZED RATIO; KINETICS; THROMBOELASTOGRAPHY; THROMBOGENESIS; THROMBUS; METABOLISM; PHYSIOLOGY; THROMBOSIS;

ANTICOAGULANTS; FIBRINOLYSIS; HUMANS; INTERNATIONAL NORMALIZED RATIO; THROMBOPLASTIN; THROMBOSIS; WARFARIN;

EID: 62449289129     PISSN: 10582916     EISSN: None     Source Type: Journal    
DOI: 10.1097/MAT.0b013e318190c1a9     Document Type: Article

References (17)

1. Akins CW: Results with mechanical valvular prostheses. Ann Thorac Surg 60: 1836-1844, 1995.
2. Schapkaitz E, Jacobson BF, Becker P, Conway G: Thrombo-embolic and bleeding complications in patients with mechanical valve replacements - A prospective observational study. S Afr Med J 96: 710-713, 2006.
3. Bayliss A, Faber P, Dunning J, Ronald A: What is the optimal leve of anticoagulation in adult patients receiving warfarin following implantation of a mechanical prosthetic mitral valve? Interact Cardiovasc Thorac Surg 6: 390-396, 2007.
4. Koertke H, Zittermann A, Tenderich G, et al : Low-dose oral anticoagulation in patients with mechanical heart valve prostheses: Final report from the early self-management anticoagulation trial II. Eur Heart J 28: 2479-2484, 2007.
5. Leissinger CA, Blatt PM, Hoots WK, Ewenstein B: Role of prothrombin complex concentrates in reversing warfarin anticoagulation: A review of the literature. Am J Hematol 83: 137-143, 2008.
6. Nielsen, VG, Kirklin JK, Holman WL, et al : Mechanical circulatory device thrombosis: A new paradigm linking hypercoagulation and hypofibrinolysis. ASAIO J 54: 351-358, 2008.
7. Nielsen VG, Steenwyk BL, Gurley WQ: Contact activation prolongs clot lysis time in human plasma: Role of thrombin activatable fibrinolysis inhibitor and factor XIII. J Heart Lung Transplant 25: 1247-1252, 2006.
8. Nielsen VG, Cohen BM, Cohen E: Elastic modulus-based thrombelastographic quantification of plasma clot fibrinolysis with progressive plasminogen activation. Blood Coagul Fibrinolysis 17: 75-81, 2006.
9. Nielsen VG, Cohen BM, Cohen E: Effects of coagulation factor deficiency on plasma coagulation kinetics determined via Thrombelastography®: Critical roles of fibrinogen and factors II, VII, X and XII. Acta Anaesthesiol Scand 49: 222-231, 2005.
10. Nielsen VG: Clot lifespan model analysis of clot growth and fibrinolysis in normal subjects: Role of thrombin activatable fibrinolysis inhibitor. Blood Coagul Fibrinolysis 19: 283-287, 2008.
11. Jerkeman A, Astermark J, Hedner U, et al : Correlation between different intensities of anti-vitamin K treatment and coagulation parameters. Thromb Res 98: 467-471, 2000.
12. Sarode R, Rawal A, Lee R, et al : Poor correlation of supratherapeutic international normalized ratio and vitamin K-dependent procoagulant factor levels during warfarin therapy. Br J Haematol 132: 604-607, 2005.
13. Taketomi T, Szlam F, Bader SO, et al: Effects of recombinant activated factor VII on thrombin-mediated feedback activation of coagulation. Blood Coagul Fibrinolysis 19: 135-141, 2008.
14. Ulmer JS, Lindquist RN, Dennis MS, Lazarus RA: Ecotin is a potent inhibitor of the contact system proteases factor XIIa and plasma kallikrein. FEBS Lett 365: 159-163, 1995.
15. Isawa H, Orito Y, Iwanaga S, et al: Identification and charac- terization of a new kallikrein-kinin system inhibitor from the salivary glands of the malaria vector mosquito Anopheles stephensi. Insect Biochem Mol Biol 37: 466-477, 2007.
16. 2-antiplasmin-plasmin interactions. Blood Coagul Fibrinolysis 18: 647-656, 2007.
17. Nielsen VG, Kirklin JK: Argatroban enhances fibrinolysis by differential inhibition of thrombin-mediated activation of thrombin activatable fibrinolysis inhibitor and factor XIII. Blood Coagul Fibrinolysis 19: 793-800, 2008.